Alpelisib (BYL719)
Alpelisib (BYL719) Basic information
- Product Name:
- Alpelisib (BYL719)
- Synonyms:
-
- (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide
- BYL-719
- BYL-719 /BYL719
- Alpelisib
- BLV-719
- (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxaMide
- ALPELISIB;BYL-719; BYL 719
- CS-614
- CAS:
- 1217486-61-7
- MF:
- C19H22F3N5O2S
- MW:
- 441.47
- Product Categories:
-
- Inhibitors
- Akt
- PI3K/Akt/mTOR
- mTOR
- PI3K
- Api
- API
- Mol File:
- 1217486-61-7.mol
Alpelisib (BYL719) Chemical Properties
- Density
- 1.391
- storage temp.
- Store at -20°C
- solubility
- ≥22.07 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
- form
- White solid.
- pka
- 6.29±0.70(Predicted)
- color
- Off-white to light yellow
- InChIKey
- STUWGJZDJHPWGZ-LBPRGKRZSA-N
- SMILES
- N1(C(NC2=NC(C)=C(C3C=CN=C(C(C)(C)C(F)(F)F)C=3)S2)=O)CCC[C@H]1C(N)=O
Alpelisib (BYL719) Usage And Synthesis
Description
BYL719 is an inhibitor of phosphoinositide 3-kinase α (PI3Kα; IC50s = 4.6, 4, and 4.8 nM for wild-type, E545K mutant, and H1047R mutant PI3K, respectively). It is selective for PI3Kα over PI3Kβ, PI3Kδ, PI3Kγ, and PI4Kβ (IC50s = 1,156, 290, 250, and 581 nM, respectively), as well as VPS34, mTOR, DNA-PK, and ATR (IC50s = >9,100 nM for all). BYL719 (12.5, 25, and 50 mg/kg) reduces tumor volume in a PI3Kα-dependent Rat1-myr-p110α mouse xenograft model. It also reduces tumor burden in THP-1 acute myeloid leukemia (AML) and MCF-7 breast cancer mouse xenograft models. Formulations containing BYL719 have been used in the treatment of advanced or metastatic breast cancer.
Uses
(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide is a newly developed phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor for the treatment of proliferative diseases.
Definition
ChEBI: (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide is a proline derivative.
brand name
Piqray
General Description
Class: lipid kinase; Treatment: breast cancer; Other name: NVP-BYL719; Elimination half-life = 13.7 h; Protein binding = 89%
target
PI3Kα
References
1. furet p, guagnano v, fairhurst ra et al. discovery of nvp-byl719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. bioorg med chem lett 2013; 23: 3741-3748. 2. azab f, vali s, abraham j et al. pi3kca plays a major role in multiple myeloma and its inhibition with byl719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. br j haematol 2014; 165: 89-101. 3. juric d, argiles g, burris h et al. phase i study of byl719, an alpha-specific pi3k inhibitor, in patients with pik3ca mutant advanced solid tumors: preliminary efficacy and safety in patients with pik3ca mutant er-positive (er+) metastatic breast cancer (mbc). cancer res 2012; 72: p6-10.
Alpelisib (BYL719)Supplier
- Tel
- 0539-0539-8613587 17661611089
- 2639273505@qq.com
- Tel
- +86-2332782371 +86-18120098618
- sales@adobechem.com
- Tel
- 0531-86092839 13153040268
- 2425815073@qq.com
- Tel
- 13256107535
- mahaiyan1123@126.com
- Tel
- 021-021-33632979 15002134094
- marketing@targetmol.com
Alpelisib (BYL719)(1217486-61-7)Related Product Information
- D-ERYTHRO-SPHINGOSINE
- BKM120 (NVP-BKM120, Buparlisib)
- MK-2206 2HCl
- CAL-101
- Trametinib
- 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE, 7-METHYL-2-(4-MORPHOLINYL)-9-[1-(PHENYLAMINO)ETHYL]-
- BEZ235 (NVP-BEZ235, Dactolisib)
- KU-55933
- Selumetinib
- BML-275
- PLX-4720
- CX-4945
- Fluoxetine hydrochloride
- Tubastatin A hydrochloride
- N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride
- BI 2536
- Neratinib
- Glucagon Receptor Antagonist I